SEROLOGICAL OUTCOMES OF TREATMENT WITH 3D-CRT AND IMRT IN LOCALIZED PROSTATE CANCER

Area of Science:

• Oncology
• Radiation Oncology

Background:

• Prostate cancer is a leading cancer in men globally.
• Radiotherapy is a primary treatment for localized prostate cancer.
• Advanced techniques like IMRT and 3D-CRT have improved treatment delivery.

Purpose of the Study:

• To compare the serological outcomes of IMRT and 3D-CRT for localized prostate adenocarcinoma.
• To evaluate the effectiveness of these radiotherapy techniques in reducing prostate-specific antigen (PSA) levels.

Main Methods:

• A cohort study of 78 patients with localized prostate adenocarcinoma.
• Patients received either IMRT or 3D-CRT with a total dose >74 Gy.
• Serum PSA levels were measured pre-treatment, 6 weeks, and 12 months post-treatment.

Main Results:

• Both IMRT and 3D-CRT significantly reduced PSA levels at 6 weeks (p=0.001).
• No significant difference in PSA reduction was observed between IMRT and 3D-CRT at 6 weeks and 12 months.
• Both methods demonstrated significant PSA reduction compared to baseline at 12 months with acceptable toxicity.

Conclusions:

• IMRT and 3D-CRT are effective radiotherapy modalities for localized prostate cancer.
• 3D-CRT demonstrated comparable serological response to IMRT with potentially lower gastrointestinal and genitourinary toxicities.
• 3D-CRT may be a more cost-effective option for patients unable to afford IMRT.